ASCO Genitourinary Cancers Symposium 2025 (Videos + Slides + Posters)

ASCO Genitourinary Cancers Symposium 2025 — On-Demand Access

Multidisciplinary Breakthroughs in Prostate, Bladder, Kidney & Testicular Cancer

179.99$ Instead of 1300$

Three data-packed days deliver late-breaking trial results, practice-changing guidelines, and pipeline science across prostate, urothelial, renal-cell, adrenal, penile, testicular, and germ-cell malignancies.

What You’ll Learn

• Integrate PARP, ARPI, and radioligand combinations into metastatic-prostate algorithms.

• Apply adjuvant and neoadjuvant immunotherapy results to muscle-invasive bladder cancer.

• Select optimal TKI/IO sequences and biomarkers for advanced renal-cell carcinoma.

• Evaluate ctDNA, gene signatures, and imaging tools for minimal-residual disease detection.

• Navigate antibody–drug conjugate (ADC) toxicities and combination strategies in urothelial cancer.

• Address disparities in GU-cancer care and implement advocacy initiatives.

What’s Inside? — Program Highlights

Day 1 • Prostate Cancer Focus

• Oral Abstract A — Gene-signature radiation dosing • TALAPRO-2 OS update • STOPCAP meta-analysis

• Radioligand Therapy Masterclass — PSMA-Lutetium evidence, response metrics, ctDNA correlates

• Case-Based Board Review — Biochemical recurrence after RT: salvage surgery vs focal ablation

• Keynote — William Dahut, MD on creative innovation for patient-centered GU care

• Oligometastatic Management Session — WOLVERINE IPD meta-analysis, MDT strategies

Day 2 • Urothelial Carcinoma & Germ Cell

• Oral Abstract B — CheckMate 274 OS data • durvalumab chemo combos • HER2 ADC trial results

• NMIBC Beyond BCG — Instillation chemo-immuno combos, device-assisted therapy debates

• ADC Deep-Dive — Nectin-4, HER2, Trop-2 conjugates + novel combinations

• ctDNA Workshop — Next-gen detection, peri-operative guidance, trial enrichment

• Germ Cell Breakout — High-dose chemo, RPLND controversies, refractory-disease pipelines

Day 3 • Renal Cell & Rare GU Tumors

• Oral Abstract C — COSMIC-313 final OS, CheckMate 9ER follow-up, KEYMAKER-U03 data

• Biomarker & Adjuvant RCC Forum — KIM-1, ctDNA MRD, risk-stratified adjuvant IO/TKI use

• Immunotherapy Failure Cases — IO-resistant RCC salvage combos, SBRT, surgery integration

• Poster C Walks — Penile, adrenal, urethral rare-tumor insights with expert commentary